Viewpoints

 
 
  • Tamoxifen or AI: Breast Cancer Subtypes Narrow Choice In early breast cancer, the biologic subtype provides a clue to the optimal choice of adjuvant endocrine therapy, as indicated by data from BIG 1-98 and discussed by Dr Lidia Schapira.
  • Sex After Cancer: The Unaddressed Issue Sex is not a regular topic between oncologist and patient. But Dr Don Dizon says it should be, given that a large majority of cancer patients and survivors have issues of sexual function.
  • New Option Emerging for Refractory mCRC Dr Alok Khorana comments on a novel agent that improves survival in refractory metastatic colorectal cancer.
  • Palliative Care: A Primer for Oncologists 'You cannot be an oncologist and not do primary palliative care,' says Dr Jennifer Temel, who advises clinicians on delivering tough messages and when to seek help from palliative care specialists.
  • Immunotherapy in Previously Treated Advanced NSCLC Dr Jack West provides an analysis of practice-changing studies presented at ASCO 2015, with a focus on lung cancer.
  • Neratinib Lowers Recurrence in High-Risk HER2+ Breast Cancer Dr Lidia Schapira gives the take-home messages from breast cancer sessions of ASCO 2015, including top studies in HER2+ and HR+ disease, and new findings for managing side effects of treatment.
  • Genomic Sequencing: Refining Lung Cancer Staging Dr Jack West comments on a very provocative proof of principle demonstrating the effect next-generation sequencing may have on tumor staging.
  • RTOG 0617 Trial: With Chest Radiation, More Is Not Better Dr Jack West discusses two studies that challenge the prevailing presumption that in cancer treatment 'more must be better' and that underscore the value of clinical trials that refute these presumptions.
  • Micromets 'No Biggie' in Early-Stage Breast Cancer Dr Lidia Schapira reports on an analysis that indicates axillary micrometastases and low-volume disease should not be used to guide systemic treatment in early breast cancer.
  • Big Benefits From Goserelin in Young Breast Cancer Patients The GnRH agonist goserelin preserved fertility and improved pregnancy and survival in ER-positive breast cancer patients receiving chemotherapy in a study discussed by Dr Lidia Schapira.
  • Tamoxifen Prevents Breast Cancer: Worth a Chat Dr Lidia Schapira reports on the published findings of the IBIS-I study, which confirm that tamoxifen prevents breast cancer in patients at increased risk. Isn't it time to have a chat with patients?
  • Second-line Oxaliplatin Benefits Pancreatic Cancer Patients Dr Alok Khorana reports on the CONKO study, which shows that patients with pancreatic cancer who receive gemcitabine in first-line therapy benefit from second-line oxaliplatin-based therapy.
  • SOFT Already Informing Choices in HR+ Breast Cancer The SOFT results, published in December, are informing clinical decisions in young women with early HR+ breast cancer, says Dr Lidia Schapira, especially those at high risk for recurrence.
  • Does SBRT Revolutionize Metastatic NSCLC? Dr Jack West argues that an encouraging new study of stereotactic body radiation therapy should not necessarily change practice.
  • Breast Cancer 2014: SOFT Proves Year's Best Dr Lidia Schapira reviews the year in breast cancer, highlighting inroads made in the individualization of care, unprecedented survival data, and the practice-changing results of the SOFT trial.
  • CMS Proviso on Lung Cancer Screening: Good or Bad? Potential barriers or appropriate guardrails? Dr Jack West comments on the recent CMS decision to cover lung cancer screening -- provided that certain conditions are met.
  • Oncology's Unrecognized Crisis Why should 71% of young oncologists in Europe report burnout? Dr Susana Banerjee, author of a much touted European survey, explains her study findings and critical issues that need to be addressed.
  • Why Are Young Oncologists Burned Out? Tim Moynihan, MD, coauthor of a landmark study on burnout in US oncology fellows, talks about the stressors that are wearing down oncologists before their careers begin.
  • BOLERO-2: OS Is So-So, but So What? Dr Lidia Schapira reports on the overall survival data from BOLERO-2 and questions whether overall survival is a valid endpoint in studies of targeted therapy in metastatic breast cancer.
  • Should PIK3CA Inform Therapy Choice in Breast Cancer? Dr Lidia Schapira reports on a study showing that PIK3CA mutations may indicate trastuzumab resistance in HER2+ breast cancer but cautions use of the biomarker as a basis for clinical decisions.